**Supplementary Table S4.** Total of publications (644) recovered from May 13th, 2022 to May 23rd, 2023 assigned to clusters by the prediction of the model. We show the manually assigned label of each cluster (Label) and the total of publications assigned to each cluster. The table is sorted in descending order by the total of publications assigned to each cluster.

| **Cluster id** | **Total of publications assigned to the cluster** | **Label** |
| --- | --- | --- |
| 104 | 62 | Multidrug-Resistance A. baumannii and Extensively Drug-Resistant A. baumannii |
| 108 | 25 | Carbapenem-resistant A. baumannii (CRAB) |
| 16 | 22 | Phage and bacteriophage |
| 18 | 19 | Antimicrobial activity of compounds |
| 93 | 16 | Biofilm formation and anti-biofilm |
| 49 | 15 | Vaccine and vaccine candidates |
| 95 | 15 | Virulence and virulence factors in A. baumannii |
| 100 | 14 | Inhibitor protein and inhibitor binding |
| 54 | 13 | Genomic analysis and genome sequences |
| 87 | 13 | Immunization and vaccine |
| 39 | 12 | Colistin resistance and heteroresistance |
| 78 | 12 | Cefiderocol against A. baumannii |
| 48 | 11 | Bacteraemia/bacteremia, risk factors, mortality, critically ill patients |
| 52 | 11 | Carbapenem-resistant A. baumannii, OXA carbapenemases, blaOXA |
| 75 | 10 | Mutants in different growth conditions |
| 84 | 10 | In vitro and in vivo studies/activity/efficacy |
| 3 | 9 | Biofilm and biofilm formation |
| 19 | 9 | Structure of capsular polysaccharides |
| 21 | 9 | Intensive care units (ICUs) |
| 44 | 9 | Ventilator-associated pneumonia (VAP) |
| 106 | 9 | Crystal structures and crystallization |
| 110 | 9 | Polymyxin and polymyxin in combination with other antimicrobials |
| 6 | 8 | General aspects of drug resistance of A. baumannii |
| 46 | 8 | Peptides |
| 79 | 8 | Concentrations and MICs |
| 92 | 8 | Efflux pumps, mainly AdeABC |
| 2 | 7 | Bacteriophages and phages, mainly lytic |
| 9 | 7 | Innate immune response |
| 30 | 7 | A. baumannii in cells, mainly epithelial cells |
| 47 | 7 | Antibiotic resistance and antibiotic resistance mechanism |
| 70 | 7 | In vitro antimicrobial combination and synergy/synergistic |
| 76 | 7 | Pneumonia caused by A. baumannii |
| 96 | 7 | Sulbactam in combination with other antimicrobials |
| 98 | 7 | Risk factors for colonization and in hospitals |
| 107 | 7 | Corrigendum, erratum, correction |
| 22 | 6 | Studies of plasmids |
| 32 | 6 | Hospital and nosocomial outbreaks |
| 42 | 6 | Pseudomonas aeruginosa and A. baumannii |
| 60 | 6 | Detection of A. baumannii (PCR, rapid detection) |
| 61 | 6 | Outer membrane proteins, mainly OmpA |
| 63 | 6 | Nosocomial, clinical treatments and infections, healthcare |
| 65 | 6 | Molecular epidemiology, sequence typing and sequence types |
| 88 | 6 | Epidemiology and molecular epidemiology in hospitals |
| 101 | 6 | Meropenem in combination with other antimicrobials |
| 111 | 6 | Tigecycline, tigecycline treatment and in vitro activity of tigecycline |
| 12 | 5 | Proteins, mainly membrane proteins, in proteomic analysis |
| 24 | 5 | Silver, silver nanoparticles, and silver nanocomposite |
| 27 | 5 | Ventriculitis and intraventricular/intravenous colistin |
| 36 | 5 | Pseudomonas aeruginosa and A. baumannii |
| 51 | 5 | blaOXA genes and blaNDM genes |
| 53 | 5 | Case reports of illness caused by A. baumannii |
| 55 | 5 | Different systems in A. baumannii, some with metals (copper, zinc) |
| 56 | 5 | Light, blue light and photodynamic |
| 68 | 5 | Survival and degradation of A. baumannii in different conditions |
| 73 | 5 | Burns units and wound infections |
| 105 | 5 | Minocycline in combination with colistin and polymyxin |
| 26 | 4 | Genetic studies, gene mutations (gyrA, parC) |
| 57 | 4 | Beta-lactam and beta-lactamase inhibitor |
| 59 | 4 | Animals, animal model and veterinary |
| 66 | 4 | OXA beta-lactamase and OXA carbapenemase in carbapenem resistance |
| 69 | 4 | Colistin-resistant mutations |
| 71 | 4 | Risk factors for mortality in bacteremia |
| 97 | 4 | Mouse model, mainly pneumonia and lung infection |
| 102 | 4 | Quorum sensing, biofilm and quorum quenching |
| 1 | 3 | Susceptibility testing, E-test, tigecycline susceptibility |
| 4 | 3 | Gene expression, several mentions of acid |
| 10 | 3 | A. baumannii in human body louse, meat, animals, extrahuman parts |
| 20 | 3 | Human serum and human serum albumin (HSA) |
| 29 | 3 | Environmental contamination and cleaning during outbreaks, mainly in hospitals and intensive care units |
| 31 | 3 | Complete genome studies |
| 41 | 3 | Outer membrane vesicles |
| 45 | 3 | Mechanisms of carbapenem resistance, mainly in hospitals |
| 50 | 3 | Iron and siderophores |
| 74 | 3 | Secretion system, mainly vgrG/VgrG |
| 80 | 3 | Analysis of DNA, mainly amplification and amplified analysis |
| 90 | 3 | Systematic review and meta-analysis |
| 14 | 2 | Different aspects of multidrug-resistant A. baumannii |
| 33 | 2 | Clones and international/european clones in hospitals |
| 35 | 2 | Lipopolysaccharide, loss of lipopolysaccharide, mainly in colistin resistance |
| 38 | 2 | Efflux pumps Ade-type (AdeABC, AdeR, AdeRS) |
| 77 | 2 | Aminoglycoside and rRNA methylase |
| 82 | 2 | Combination of antibiotics against A. baumannii especially colistin, rifampicin and imipenem |
| 89 | 2 | Surface-associated motility in A. baumannii |
| 99 | 2 | Typing methods: pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST) |
| 11 | 1 | Carbapenem-resistant A. baumannii, blaOXA genes and OXA genes |
| 15 | 1 | Polymyxin and metabolic/metabolomic studies |
| 17 | 1 | Carbapenem-resistant OXAs from hospitals |
| 23 | 1 | Resistance islands, mainly AbaR-type and AbGRI-type |
| 25 | 1 | Community-acquired infections, mainly pneumonia |
| 28 | 1 | Carbapenem resistance, OXA-type carbapenemase, blaOXA |
| 40 | 1 | Metallo-beta-lactamase (MBL), mainly in carbapenem-resistant A. baumannii |
| 43 | 1 | Species of A. baumannii, mainly Acinetobacter calcoaceticus-Acinetobacter baumannii complex |
| 62 | 1 | Class 1 and 2 integrons and gene cassettes |
| 67 | 1 | Pan-drug-resistant A. baumannii in Taiwan |
| 72 | 1 | Draft genome sequences and genome sequences |
| 81 | 1 | Colonies, opacity, translucent, phenotypes |
| 86 | 1 | Beta-lactamase, mainly ADC and AmpC |
| 94 | 1 | Sepsis caused by A. baumannii |
| 109 | 1 | Extended-spectrum beta-lactamase (ESBL) (VEB, PER) |
| 112 | 1 | Methicillin-resistant Staphylococcus aureus and A. baumannii |